statistiche ricercatore

Continente	#
NA - Nord America	607
AS - Asia	314
EU - Europa	293
SA - Sud America	50
AF - Africa	5
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.271

Nazione	#
US - Stati Uniti d'America	585
SG - Singapore	100
CN - Cina	67
IT - Italia	59
IE - Irlanda	56
GB - Regno Unito	45
VN - Vietnam	44
HK - Hong Kong	43
BR - Brasile	42
SE - Svezia	34
BD - Bangladesh	22
DE - Germania	21
FI - Finlandia	18
FR - Francia	15
CA - Canada	14
RU - Federazione Russa	14
ID - Indonesia	8
BE - Belgio	5
IN - India	5
MX - Messico	5
AT - Austria	4
BG - Bulgaria	4
KR - Corea	4
PL - Polonia	4
CO - Colombia	3
IQ - Iraq	3
JP - Giappone	3
NL - Olanda	3
PY - Paraguay	3
TR - Turchia	3
AE - Emirati Arabi Uniti	2
CR - Costa Rica	2
DZ - Algeria	2
ES - Italia	2
LT - Lituania	2
UA - Ucraina	2
UZ - Uzbekistan	2
AR - Argentina	1
AU - Australia	1
BH - Bahrain	1
BJ - Benin	1
CY - Cipro	1
CZ - Repubblica Ceca	1
EC - Ecuador	1
ET - Etiopia	1
GR - Grecia	1
JO - Giordania	1
KZ - Kazakistan	1
MD - Moldavia	1
MY - Malesia	1
NG - Nigeria	1
PK - Pakistan	1
PT - Portogallo	1
RO - Romania	1
SA - Arabia Saudita	1
TW - Taiwan	1
VC - Saint Vincent e Grenadine	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.271

Nome	#
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers	296
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio	271
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y)	260
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial	234
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial	200
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study	14
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)	8
Totale	1.283

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	9	0	0	0	0	0	0	0	0	0	0	0	9
2021/2022	127	3	20	1	4	2	12	9	1	19	11	33	12
2022/2023	172	11	25	7	13	11	19	2	14	62	0	2	6
2023/2024	76	2	5	6	4	13	2	14	12	0	3	5	10
2024/2025	251	9	0	3	17	45	48	16	15	29	3	22	44
2025/2026	496	37	16	41	64	73	22	50	28	35	44	69	17
Totale													1.283